Skip to main content

Table 2 Distribution of the COMT Val108/158Met and DBH-1021C/T genotypes in patients with type 2 diabetes (T2DM patients) and healthy controls, and in subjects subdivided according to gender

From: The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus

  COMT Val108/158Met DBH-1021C/T
T2DM/controls AA AG GG CC CT TT
T2DM patients 39 (21.1%) 101 (54.6%) 45 (24.3%) 113 (61.1%) 64 (34.6%) 8 (4.3%)
Healthy controls 36 (23.1%) 80 (51.3%) 40 (25.6%) 94 (60.3%) 56(35.9%) 6 (3.8%)
χ2 test χ2 = 0.389; df = 2; p = 0.824 χ2 = 0.097; df = 2; p = 0.952
T2DM women 25 (21.7%) 61 (53.1%) 29(25.2%) 68 (59.1%) 42 (36.5%) 5 (4.4%)
Healthy women 27 (26%) 49 (47.1%) 28 (26.9%) 63 (60.6%) 36 (34.6%) 5 (4.8%)
χ2 test χ2 = 0.853; df = 2; p = 0.653 χ2 = 0.100; df = 2; p = 0.951
T2DM men 14 (20%) 40 (57.1%) 16 (22.9%) 45 (64.3%) 22 (31.4%) 3 (4.28%)
Healthy men 9 (17.3%) 31 (59.6%) 12 (23.1%) 31 (59.6%) 20 (38.5%) 1 (1.9%)
χ2 test χ2 = 0.147; df = 2; p = 0.929 χ2 = 1.041; df = 2; p = 0.594